Immunomedics Partner Resumes Trial
16th Nov 2006, 08:21 GMT
Drug developer Immunomedics said its licensing partner for a lupus treatment, UCB SA, would resume clinical trials after the FDA lifted its hold on the project.
Immunomedics Partner Resumes Trial related news:
- FDA Allows Resumption of Lupus Trials with Epratuzumab — Government/ Industry Regulation News from StratCenter.com
- SurfControl Rolls Out Enhanced Partner Program and Launches New Partner Portal — ArriveNet : Technology
- Zenprise Attains Gold Certified Partner Status in Microsoft Partner Program — RedOrbit News - Technology
- SurfControl: SurfControl Rolls Out Enhanced Partner Program and Launches New Partner Portal — Market Wire - Computers and Software
- oprandi & partner auf Wachstumskurs — openPR.de Newsfeed : "Handel, Wirtschaft, Finanzen, Banken & Versicherungen"
- Novell Enhances Business Value of Working with Novell in PartnerNet 2007 — WebWire - Recent Headlines
- Taiwan courts brace for trial of first lady — Reuters: World
- Judge Postpones KPMG Trial Date — WSJ.com: What's News US
- Heart conference: Controversy over failed drug trial — Business and financial news - CNNMoney.com
- Paul Hastings hires King & Spalding partner — bizjournals.com Business Services:Legal Services headlines
Latest news from FDA News News from StratCenter.com:
- North American Gets Cancer Treatment OK
- North American Scientific Announces FDA Clearance of its ClearPath HDR Breast Brachytherapy System
- Newly FDA Approved SmartLipo Laser Liposuction Available at the Intimate Rejuvenation and Innovative Surgery Center, Phoenix, AZ.
- ACT-AD Coalition Calls FDA's New Focus on Neurological Diseases a Positive 1st Step
- Ivax Diagnostics Delays Filing 3Q Report
- New Corporate Members and Leaders for C-Path's Predictive Safety Testing Consortium Announced
- Diagnosoft Receives FDA Approval for Cardiac MRI Quantitative Regional Function Software Based on the HARP Technology
- PAREXEL Consulting Expands Risk Mgmt Expertise, Appoints Former FDA Consumer Safety Officer Raymond T Oji as Senior Consultant
- Trubion Pharmaceuticals to Present at the Lazard Life Sciences Conference
- Critical Therapeutics Announces Efficacy Data for Controlled-Release Formulation of Zileuton Presented at ACAAI 2006 Annual Meeting